PMID- 31631085
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200108
IS  - 1884-7110 (Electronic)
IS  - 0021-5287 (Linking)
VI  - 109
IP  - 4
DP  - 2018
TI  - [EFFICACY AND SAFETY OF PAZOPANIB FOR ADVANCED OR METASTATIC RENAL CELL 
      CARCINOMA: A SINGLE-INSTITUTION STUDY].
PG  - 216-219
LID - 10.5980/jpnjurol.109.216 [doi]
AB  - To investigate the efficacy and safety of first-line Pazopanib advanced or 
      metastatic renal cell carcinoma (RCC): a single-institution study. (Patients and 
      methods) We gathered 23 RCC patients treated between April 2014 and February 2018 
      in our institution and examined the treatments outcome and adverse events (AEs). 
      (Results) Their risk criteria were categorized as follows: Favorable (n=2), 
      Intermediate (n=12) and Poor (n=9) by International mRCC Database Consortion 
      (IMDC). Median progression free survival (PFS) was 8.6 months and median overall 
      survival (OS) was unreached. Best response (BR) of Pazopanib was partial response 
      (PR): n=10, 50.0%, stable disease (SD): n=8, 40.0% and progression disease (PD): 
      n=2, 10.0% (Three patients had no evaluable data,). AEs of Grade3 had liver 
      dysfunction (n=3), thrombocytopenia (n=2), hand-foot syndrome (n=1), vomiting 
      (n=1) and bowel bleeding (n=1). (Conclusion) The fist-line pazopanib demonstrated 
      good clinical benefit with well-tolerance.
FAU - Harada, Kenichi
AU  - Harada K
AD  - Department of Urology, Kobe Uuiversity Graduate School of Medicine.
FAU - Shiraishi, Yusuke
AU  - Shiraishi Y
AD  - Department of Urology, Kobe Uuiversity Graduate School of Medicine.
FAU - Suzuki, Kohtaro
AU  - Suzuki K
AD  - Department of Urology, Kobe Uuiversity Graduate School of Medicine.
FAU - Okamura, Yasuyoshi
AU  - Okamura Y
AD  - Department of Urology, Kobe Uuiversity Graduate School of Medicine.
FAU - Bando, Yukari
AU  - Bando Y
AD  - Department of Urology, Kobe Uuiversity Graduate School of Medicine.
FAU - Hara, Takuto
AU  - Hara T
AD  - Department of Urology, Kobe Uuiversity Graduate School of Medicine.
FAU - Terakawa, Tomoaki
AU  - Terakawa T
AD  - Department of Urology, Kobe Uuiversity Graduate School of Medicine.
FAU - Furukawa, Junya
AU  - Furukawa J
AD  - Department of Urology, Kobe Uuiversity Graduate School of Medicine.
FAU - Ishimura, Takeshi
AU  - Ishimura T
AD  - Department of Urology, Kobe Uuiversity Graduate School of Medicine.
FAU - Shigemura, Katsumi
AU  - Shigemura K
AD  - Department of Urology, Kobe Uuiversity Graduate School of Medicine.
FAU - Hinata, Nobuyuki
AU  - Hinata N
AD  - Department of Urology, Kobe Uuiversity Graduate School of Medicine.
FAU - Nakano, Yuzo
AU  - Nakano Y
AD  - Department of Urology, Kobe Uuiversity Graduate School of Medicine.
FAU - Fujisawa, Masato
AU  - Fujisawa M
AD  - Department of Urology, Kobe Uuiversity Graduate School of Medicine.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Hinyokika Gakkai Zasshi
JT  - Nihon Hinyokika Gakkai zasshi. The japanese journal of urology
JID - 2984841R
SB  - IM
OTO - NOTNLM
OT  - first line therapy
OT  - pozopanib
OT  - renal cell carcinoma
EDAT- 2018/01/01 00:00
MHDA- 2018/01/01 00:01
CRDT- 2019/10/22 06:00
PHST- 2019/10/22 06:00 [entrez]
PHST- 2018/01/01 00:00 [pubmed]
PHST- 2018/01/01 00:01 [medline]
AID - 10.5980/jpnjurol.109.216 [doi]
PST - ppublish
SO  - Nihon Hinyokika Gakkai Zasshi. 2018;109(4):216-219. doi: 
      10.5980/jpnjurol.109.216.